carbidopa /car·bi·do·pa/ (kahr″bĭ-do´pah) an inhibitor of decarboxylation of levodopa in extracerebral tissues, used in combination with levodopa as an antiparkinsonian agent.
carbidopa
carbidopa [kahr-bĭ-do´pah]
car·bi·do·pa (kär b -d  p )n. A drug that increases the availability of L-dopa to the brain and is administered with it in the treatment of Parkinson's disease |
carbidopa
[kär′bidō′pə]
a dopa decarboxylase inhibitor that cannot cross the blood-brain barrier.
indication It is prescribed in combination with levodopa in the treatment of idiopathic Parkinson's disease because it inhibits the degradation of levodopa in the periphery, thereby permitting a larger percentage of orally administrated doses to enter the brain.
contraindications Glaucoma, hypertension, use of a monoamine oxidase inhibitor within the past 14 days, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the most serious adverse reactions are GI bleeding, cardiac irregularity, hemolytic anemia, tardive dyskinesia, mental depression, blurred vision, and activation of malignant melanoma.
carbidopa [kahr-bĭ-do´pah]
an inhibitor of the decarboxylation of levodopa in peripheral tissues; it does not cross the blood-brain barrier and is used in combination with levodopa to control the symptoms of parkinson's disease. In the presence of carbidopa, levodopa enters the brain in larger quantities, thus avoiding the need for excessively high doses of levodopa.
Want to thank TFD for its existence? Tell a friend about us, add a link to this page, add the site to iGoogle, or visit the webmaster's page for free fun content.
| ?Page tools | ||
|---|---|---|
|